Form 4: Amgen CEO Bradway Sells Shares for Tax Obligations

Amgen's Chairman, CEO, and President, Robert A. Bradway, disposed of 21,294 shares of common stock at $366.21 per share to cover tax liabilities.

Summary

• Robert A. Bradway, Amgen's Chairman, CEO, and President, reported a transaction involving Amgen common stock.
• On March 16, 2026, Bradway disposed of 21,294 shares of Amgen common stock.
• The shares were disposed of at a price of $366.21 per share.
• This transaction was coded 'F', indicating the shares were withheld to cover tax liabilities related to the vesting of restricted stock or exercise of options.
• Following this transaction, Bradway directly owns 501,862 shares, which include 2,696 Dividend Equivalents.
• Indirect holdings include 60,060 shares by GRAT, 60,060 shares by Spousal GRAT, and 29,940 shares by Spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a non-discretionary sale for tax purposes, which is a common and expected occurrence for executives.

Positives

• The transaction is a non-discretionary sale to cover tax obligations, not a sale driven by a change in investment outlook.

Negatives

• No specific negatives related to company performance or outlook are indicated by this filing.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those coded 'F' for tax purposes, are generally considered routine and do not typically reflect a change in the company's operational performance or the insider's confidence in the company's future.

Related Party Transactions

• Indirect beneficial ownership includes 60,060 shares held by a GRAT, 60,060 shares held by a Spousal GRAT, and 29,940 shares held by the reporting person's spouse.

Stakeholder Impact

• Shareholders: Minor impact from the sale of shares, but the non-discretionary nature suggests no change in management's confidence.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by Amgen's CEO to cover tax obligations. Such transactions are common for executives receiving equity compensation and do not typically signal a change in the company's fundamentals or management's long-term outlook. Therefore, it provides no new information to warrant a change in investment recommendation based solely on this filing.

Keywords

Amgen, AMGN, Robert A. Bradway, insider trading, SEC Form 4, stock transaction, CEO, Chairman, President, common stock, equity, tax liability